Latest / Raleigh News Today | 2 Min News | The Daily News Now!
Jazz Bets Big on Rare Epilepsy Drug | Raleigh News
Jazz Pharmaceuticals just splashed eight hundred twenty million dollars to acquire Actio Biosciences, eyeing their experimental drug ABS-1230 for a devastating, treatment-resistant childhood epilepsy with zero FDA-approved options. The move, timed with record sales, signals confidence—not desperation—and could unlock a future monopoly in a blank market. Early data shows promise, with seizure reductions and fast-track regulatory designations boosting odds. With potential upside hitting $1.32 billion and trial results due by 2027, investors are watching closely to see if Jazz’s bold bet pays…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.